New Mexico VA Health Care System, Albuquerque, NM, USA.
Cardiol Rev. 2010 Jan-Feb;18(1):51-6. doi: 10.1097/CRD.0b013e3181c61b52.
Thiazide diuretics are a mainstay for the treatment of hypertension. Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure. This is despite several clinical trials that have used and documented the benefits of chlorthalidone for hypertension management. In terms of blood pressure lowering, both HCTZ and chlorthalidone appear to be very effective. Head-to-head studies have shown trends favoring chlorthalidone as a more effective blood pressure lowering agent compared with HCTZ, but statistical significance in this regard has not been consistently demonstrated. Also unclear is the relative benefits of these 2 drugs with regards to reducing clinical complications of hypertension, namely cardiovascular morbidity and mortality. Whereas there is more aggregate clinical trial data documenting the benefits of chlorthalidone compared with HCTZ in terms of hard clinical outcomes, these trials are not direct comparisons and can only be used to fuel the debate as to which of the 2 thiazides are better. From a safety perspective, hypokalemia is a risk with any of the thiazide diuretics and has been shown to be dose-related. However, at equipotent dosages, the incidence of hypokalemia between chlorthalidone and HCTZ appears comparable. The available evidence therefore supports both HCTZ and chlorthalidone as safe and effective drugs for treating hypertension. Although there are favorable trends both in terms of antihypertensive efficacy as well as clinical outcomes data with chlorthalidone compared with HCTZ, the results are not conclusive, and as such may not be enough to shift the treatment paradigm in favor of chlorthalidone, given the comfort level that most prescribers have with HCTZ. A head-to-head study looking at hard clinical outcomes, which may or may not ever be performed, may be the only way to resolve the ongoing debate as to which is the preferred thiazide for treating hypertension.
噻嗪类利尿剂是治疗高血压的主要药物。虽然目前有几种噻嗪类利尿剂可供选择,但氢氯噻嗪(HCTZ)仍然是治疗高血压最常用的噻嗪类药物。尽管有几项临床试验已经使用并记录了氯噻酮在高血压管理中的益处。就降低血压而言,HCTZ 和氯噻酮似乎都非常有效。头对头研究表明,氯噻酮在降低血压方面比 HCTZ 更有效,但在这方面并未始终显示出统计学意义上的显著差异。也不清楚这两种药物在降低高血压的临床并发症(即心血管发病率和死亡率)方面的相对益处。虽然有更多的汇总临床试验数据记录了氯噻酮在硬临床结局方面相对于 HCTZ 的益处,但这些试验并非直接比较,只能用于激发关于哪种噻嗪类药物更好的争论。从安全性角度来看,低钾血症是所有噻嗪类利尿剂的风险,并且与剂量有关。然而,在等效剂量下,氯噻酮和 HCTZ 之间低钾血症的发生率似乎相当。因此,现有证据支持 HCTZ 和氯噻酮作为治疗高血压的安全有效药物。尽管与 HCTZ 相比,氯噻酮在降压疗效和临床结局数据方面都有有利趋势,但结果并不确定,因此可能不足以改变以氯噻酮为治疗高血压的治疗模式,因为大多数处方医生对 HCTZ 的舒适度水平。一项针对硬临床结局的头对头研究,可能会进行,也可能不会进行,可能是解决关于哪种噻嗪类药物是治疗高血压的首选药物的持续争论的唯一方法。